Incyte INCY recently announced that the European Commission has approved a label expansion of oncology drug Zynyz ...

A drug which can slow the growth of brain tumours has been approved for use on NHS Scotland, following a campaign by those affected ...

As a full-time practicing medical oncologist in Winchester, I spend my days with Virginians who bravely fight cancer. Sadly, ...

A drug which can slow the growth of brain tumours has been approved for use on NHS Scotland, following a campaign by those affected ...

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Rising NEC Incidence: The global increase in diagnosed cases of neuroendocrine tumors (including carcinomas) is a major market growth driver. This uptick is driven by better detection and reporting, ...

Coiled Therapeutics (AIM:COIL) co-founder and incoming executive chair Dr Sotirios Stergiopoulos talked with Proactive's Stephen Gunnion about the company’s planned market debut via a reverse takeover ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate ...

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...